UNSPSC 51292015: Nisoxetine

This classification denotes an antidepressant agent with the molecular formula C17H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17NV064B2D, chemically known as benzenepropanamine, gamma-(2-methoxyphenoxy)-n-methyl- but generally known as nisoxetine, which bears US NIH Compound Identifier 4500. European Medicines Agency schedules Nisoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09308MIG.

UNSPSC 51292015 Nisoxetine is a Commodity code that in practice spans a broader range of pharmaceutical procurement than its nominal single-substance name suggests. State and local governments currently solicit under this code for generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and direct-to-manufacturer pharmacy benefit programs. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work involves establishing supply contracts for pharmaceutical products with specified National Drug Codes, managing quarterly or ongoing deliveries to designated health facilities, negotiating pricing through authorized wholesale channels, and in some cases restructuring pharmacy benefit delivery models away from traditional pharmacy benefit manager intermediaries.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for future procurement strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification, with contract terms of two years for new vendors effective July 1, 2026.